The Chinese Food and Drug Administration approved 3-D printed hip implants in China, encouraging innovation amid an increasingly stringent regulatory environment.
China may lead in global API manufacturing, but it wants to move up the food chain and has been enticing Indian scientists with big pay packages to get formulation expertise.
China's Jiangsu Hengrui Medicine signed a deal with U.S.-based Incyte that could be worth as much as $795 million with milestones to outlicense rights outside of Greater China for its clinical-stage anti-PD-1 monoclonal antibody candidate, the latest of a string of deals in the past few months.
China's Ascletis Pharmaceuticals has won approval to begin a Phase II trial of danoprevir (ASC08) in Taiwan in combination with ASC16 (PPI-668) for an interferon-free HCV treatment that could also help put it in pole position in the Chinese market, the company said in a press release.
A key drug company in China fired a new salvo in the online over-the-counter healthcare market with an eye on wider sales of ethical products in hopes the China Food and Drug Administration (CFDA) will come through on plans to allow online sales of prescription drugs at some point this year.
Pfizer has no problem keeping sales for Viagra flying high in China, where brand awareness campaigns and changing attitudes toward sex have given it a sizable hold on the ED market. But the company is facing some headwind in the country, as Chinese marketing authorities slapped Pfizer with a fine for paying local drugstores to promote its blockbuster ED med.
Investigational new drug applications for oncology in China may see a 60-day deadline for a thumbs up, or down, placing the country on a path already followed by Singapore, Taiwan and South Korea for quick early-stage decisions.
In a continued stream of North American dealmaking, China's Shenzhen Hepalink Pharmaceutical bought U.S.-based biologics contract manufacturer Cytovance Biologics for $205.7 million and unspecified contingency payments with plans to accelerate the target's expansion plans.
Chalk up a second one for China-focused Decheng Capital in a month as U.S.-based BD Life buys Cellular Research, one of the portfolio companies of the venture capital firm.
Illumina is joining forces with China's Burning Rock to create cancer diagnostics geared toward the Chinese market, combining its sequencing prowess with Burning Rock's research know-how to increase its footprint in the country.